Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



Regeneron Pharmaceuticals Inc REGN Q4 2024 Earnings Call Highlights: Strong Revenue Growth ... Yahoo Finance

February 10, 2025
Regeneron Pharmaceuticals Inc. (REGN) recently held its Q4 2024 earnings call, highlighting strong revenue growth and positive developments in its portfolio. The company reported notable increases in sales for its key products, driving overall revenue growth. The call also emphasized Regeneron's commitment to research and development, with several promising pipeline candidates in advanced stages of clinical trials. Investors are optimistic about the company's future prospects, as it continues to deliver innovative solutions to critical healthcare challenges. To gain expert insights into the projected movement of Regeneron Pharmaceuticals Inc. shares, it is recommended to consult professionals at Stocks Prognosis.
If you want to leave a comment, then you need Login or Register





Other data for REGN

Related data

REGNSeptember 5, 2025Regeneron Pharmaceuticals Inc. Continues to Impress Investors with Strong Performance  ~1 min.

Regeneron Pharmaceuticals Inc. (REGN) has been making waves in the stock market recently, with Evercore ISI maintaining a buy rating and a price target of 750....


REGNJuly 5, 2025Regeneron Pharmaceuticals: Revolutionizing Healthcare with Innovative Drug Approvals  ~1 min.

Regeneron Pharmaceuticals, Inc. recently made headlines with the approval of Dupixent by the US FDA, in collaboration with Sanofi....


REGNJune 27, 2025Regeneron Pharmaceuticals Inc. Continues to Impress Investors as UBS Lowers Price Target  ~1 min.

Regeneron Pharmaceuticals Inc. has been making waves in the biotech industry, with impressive financial and operating results....


REGNJune 5, 2025REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with 33.76% Profit Margin  ~1 min.

QuantWave's forecast signal for REGENERON PHARMACEUTICALS, INC. on December 13, 2024, predicted a short direction with a price of 728.18 $. On June 5, 2025, the stock reached the target price of 482....


REGNJune 5, 2025REGENERON PHARMACEUTICALS, INC. Hits Forecast Price Target with a 32.0% Profit  ~1 min.

REGENERON PHARMACEUTICALS, INC. has successfully reached the forecast price target set by QuantWave, resulting in a profit of 32.0%. The forecast signal was issued on December 31, 2024, with a price of $709....


REGNJune 4, 2025REGENERON PHARMACEUTICALS, INC. Hits QuantWave Price Target Forecast with 27.18% Profit  ~2 min.

REGENERON PHARMACEUTICALS, INC. (REGN) has successfully reached the price target forecast set by QuantWave, resulting in a profit of 27.18%....


REGNJune 4, 2025REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with Profit of 26.25%  ~1 min.

REGENERON PHARMACEUTICALS, INC. stock recently achieved the price target forecast set by QuantWave on March 21, 2025. The forecast indicated a short direction, with the stock price at $657....


REGNJune 4, 2025REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with 26.25% Profit: QuantWave's Success in Stock Prediction  ~2 min.

REGENERON PHARMACEUTICALS, INC. has recently reached the price target forecast set by QuantWave on June 4, 2025....


REGNJune 4, 2025REGENERON PHARMACEUTICALS, INC. Hits QuantWave Price Target Forecast with 27.18% Profit  ~1 min.

REGENERON PHARMACEUTICALS, INC. (ticker: REGN) has successfully achieved the price target forecast set by QuantWave, realizing a profit of 27.18%....


REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Hits QuantWave's Price Target with 20.42% Profit  ~2 min.

In a recent success story for QuantWave, the automated forecasting platform accurately predicted a short position for REGENERON PHARMACEUTICALS, INC....


REGNFebruary 9, 2025Regeneron Pharmaceuticals Inc REGN Reports Strong Earnings in Q4 2024  ~2 min.

Regeneron Pharmaceuticals Inc., a leading biotechnology company, announced its impressive financial results for the fourth quarter of 2024....


REGNJuly 5, 2025Regeneron Pharmaceuticals: Revolutionizing Healthcare with Innovative Drug Approvals  ~1 min.

Regeneron Pharmaceuticals, Inc. recently made headlines with the approval of Dupixent by the US FDA, in collaboration with Sanofi....


REGNJanuary 2, 2025Regeneron Pharmaceuticals: An Impressive 89% Return Over the Last Five Years  ~2 min.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been a rewarding investment for shareholders, with a solid 89% return over the past five years, according to Yahoo Finance....


REGNJanuary 2, 2025Regeneron Pharmaceuticals: Discoveries and Innovations Driving Growth  ~2 min.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been making significant strides in the pharmaceutical industry, driving growth and attracting investors....


REGNJanuary 2, 2025Regeneron Pharmaceuticals: A Promising Future Ahead  ~2 min.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been making significant strides in the pharmaceutical industry, with investors enjoying a decent 89% return over the past five years....